Publications by authors named "Marc Rehlinghaus"
Many systemic treatments used in genitourinary oncology negatively affect haematopoiesis, thus leading to neutropenia. Neutropenic patients are vulnerable to bacterial, and other infections. Often fever is the only symptom in these patients.
View Article and Find Full Text PDFDue to the approval of immuno-oncological therapies with immune checkpoint inhibitors, the treatment of metastatic urothelial carcinoma has become more complex in all lines of therapy. Thus, in first-line treatment, immunotherapy alone or immune maintenance therapy following platinum-based chemotherapy can be applied in addition to treatment with platinum-based combination therapies alone. In addition to the approval status and guideline recommendation, patient-specific factors such as comorbidities as well as patient preference must always be considered when choosing a therapy.
View Article and Find Full Text PDFArticle Synopsis
- Researchers are studying a type of kidney cancer called ccRCC and how a specific treatment involving anti-PD-1 can work better when combined with certain therapies.
- They found that changes in DNA, called promoter hypomethylation, can help predict how well patients will respond to the treatment.
- Analysis of patient samples showed that those with hypomethylation had better treatment outcomes but also faced poorer overall survival when first diagnosed with ccRCC.